Bristol-Myers Squibb Co

BMY

46.200USD

-1.340-2.82%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

53 / 176

Overall Ranking

166 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 29 analysts

Hold

Current Rating

51.589

Target Price

+8.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD 8.95B.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is 18.55, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.70B shares, increasing 1.81% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 193.94M shares of this stock.

The company's current financial score is 8.11, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 11.20B, representing a year-over-year decrease of 5.60%, while its net profit experienced a year-over-year decrease of 120.62%.

Score

Industry at a Glance

Previous score

8.11

Change

0



Financials

8.77

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.34

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.78

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.69

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.96

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 19.13, which is -1.94% below the recent high of 18.75 and 167.34% above the recent low of -12.88.

Score

Industry at a Glance

Previous score

3.90

Change

0.05

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 53/176

No Data

The company’s current earnings forecast score is 6.57, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for Bristol-Myers Squibb Co is 51.00, with a high of 68.00 and a low of 33.10.

Score

Industry at a Glance

Previous score

6.55

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.99, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 50.49 and the support level at 43.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.71

Change

-0.44

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 83.46%, representing a quarter-over-quarter increase of 1.01%. The largest institutional shareholder is The Vanguard, holding a total of 193.94M shares, representing 9.53% of shares outstanding, with 2.24% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

190.47M

+0.77%

BlackRock Institutional Trust Company, N.A.

97.77M

+0.78%

State Street Global Advisors (US)

94.83M

-0.33%

Charles Schwab Investment Management, Inc.

60.61M

+0.51%

JP Morgan Asset Management

69.89M

+10.76%

Capital International Investors

66.47M

+44.91%

Geode Capital Management, L.L.C.

45.45M

+2.39%

Norges Bank Investment Management (NBIM)

35.18M

+7.92%

Columbia Threadneedle Investments (US)

29.03M

+1.88%

Wellington Management Company, LLP

23.73M

+296.96%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.14, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Bristol-Myers Squibb Co

BMY

6.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.